The advertisement promotes Repatha® (evolocumab) as a treatment for very high-risk ASCVD patients, emphasizing the importance of meeting specific LDL-C reduction goals as per the 2022 ACC ECDP recommendations.
Creative Information
| CID: | e8bdc41f-79c9-43cf-a993-03a270136c6f |
| CRID: | 89_188114 |
| Domain: | repatha.com |
| Seat: | DInt |
| Size: | 300x250 |
| Bid: | $3.32 |
| Timestamp: | 10/31/2025, 6:33:45 PM |
| Declared IAB Categories: |
Analysis
5 succeeded(100% complete)
| Task | Status | Last Updated | Duration | Actions |
|---|---|---|---|---|
| ad_analysis | success | 1/4/2026, 3:03:26 AM | 4.94s | |
| adomain_analysis | success | 1/4/2026, 3:03:25 AM | 3.23s | |
| adomain_capture | success | 1/4/2026, 3:03:22 AM | 0.12s | |
| ad_render | success | 1/4/2026, 3:03:21 AM | 23.28s | |
| brand_mapping | success | 1/4/2026, 3:02:57 AM | 0.12s | |
Analysis Results
| Size: | 300x250 | ||||||||||||||||||||||
| Data Transferred: | 1668.56 KB | ||||||||||||||||||||||
| Render Time: | 9.45 Seconds | ||||||||||||||||||||||
| Creative Inferred IAB Categories: |
| ||||||||||||||||||||||
| Creative Inferred IAB Ad Products: |
| ||||||||||||||||||||||
| Domain Inferred IAB Categories: |
| ||||||||||||||||||||||
| Domain Inferred IAB Ad Products: |
| ||||||||||||||||||||||
| Landing Page: | Domain:www.repatha.com Brand: | ||||||||||||||||||||||
| Total Ad Size: | 1730.52 KB | ||||||||||||||||||||||
| Requests Made: |
|
Advertiser Domain

Ad Preview
Landing Page

Creatives


